$LLY News and Market Events
Every $LLY story Market Flux has tracked.
- Last 7 days
- 3 stories
- Previous 7 days
- 1 story
- Latest story
- Related topics
- Healthcare, Stock Markets, Corporate Actions
- Market Flux Event
Eli Lilly Foundayo Obesity Pill Cuts Sleep Apnea Disruptions by 44% in Phase 3 Trial Ahead of FDA Filing
Eli Lilly reported positive Phase 3 results for Foundayo, its once-daily oral GLP-1 drug, showing significant reductions in breathing disruptions for adults with moderate-to-severe…
- Top Story
FDA Orders Vision-Loss Warning Labels on GLP-1 Drugs Including Ozempic and Zepbound
The U.S. Food and Drug Administration on November 9 ordered the makers of blockbuster GLP-1 drugs to add warnings about a rare but potentially permanent eye condition to their product…
- Market Flux Event
Eli Lilly Partners With Hims & Hers to Sell Zepbound and Foundayo Directly Through Telehealth Platform
Eli Lilly has struck a direct-to-consumer distribution deal with Hims & Hers Health, allowing the telehealth platform to offer two of Lilly's FDA-approved GLP-1 weight-loss medicines at…
- Top Story
Eli Lilly Surges on Mounjaro Blowout as DoorDash Announces $17B Instacart Deal in Busy Earnings Session
Eli Lilly delivered the most striking result of a packed earnings day, reporting third-quarter revenue of $24.4 billion against a Wall Street estimate of $22.5 billion, a 39 percent…
- Market Flux Event
Eli Lilly's Retatrutide Delivers More Than Double the Weight Loss of Ozempic in Phase 3 Diabetes Trial
Eli Lilly's investigational drug retatrutide produced more than twice the average weight loss of Novo Nordisk's Ozempic at its highest approved dose in an 80-week Phase 3 trial enrolling…
- Top Mover
Eli Lilly Hits All-Time High Above $1,293 as Goldman Sachs Raises Price Target to $1,413
Eli Lilly shares surged roughly 4-5% on October 20 to a record high of $1,293.11, with the stock adding approximately $41 billion in market value in a single session and pushing the…
- Market Flux Event
Moderna Surges 7% Ahead of Phase 3 Melanoma Vaccine Readout as Healthcare Sector Hits Record Highs
Healthcare stocks led Wall Street higher on Tuesday, October 20, with the sector hitting record highs and Eli Lilly touching a new all-time high. Moderna shares jumped 7% to $241, drawing…
- Market Flux Event
S&P 500 Gains 0.33% as US Markets Add $330 Billion in Value
US equity markets closed higher on October 15, with the S&P 500 rising 0.33% and the Dow Jones Industrial Average leading gains at 1.08%, while the Nasdaq edged up 0.08%. Total US market…
- Top Mover
Eli Lilly Gains $40 Billion in Market Cap as Tech Selloff Drives Rotation Into Pharma
Eli Lilly shares climbed 3.59% on October 15, adding roughly $40 billion in market value and standing out as the single biggest gainer in a session that saw the broader U.S. market shed…
- Top Mover
AbbVie Shares Hit All-Time High of 283.44 as SKYRIZI Crohn's Data and Sector Rally Drive Surge
AbbVie shares climbed to an all-time high of 283.44 on October 14, 2026, propelled by a broader healthcare sector rally that also lifted Eli Lilly and Merck, and by renewed investor focus…
- Market Flux Event
BioNTech mRNA Cancer Drug Fails First Primary Endpoint in Head and Neck Trial, Stock Slides
BioNTech's mRNA-based cancer therapy missed the first of two dual primary endpoints in a mid-stage clinical trial targeting head and neck cancer, the company disclosed on October 13. The…
- Market Flux Event
Eli Lilly Says Zepbound Outperforms Higher-Dose Wegovy in New Weight Loss Data, and Touts Foundayo Edge Over Ozempic Pill
Eli Lilly released new clinical data on September 29 showing that its obesity drug Zepbound delivered greater weight loss than a higher-dose version of Novo Nordisk's Wegovy, extending…
- Market Flux Event
Oura Pulls Nasdaq IPO Scheduled for This Week Citing Market Uncertainty
Smart ring maker Oura postponed its planned Nasdaq debut on Tuesday, September 29, citing uncertainty in the IPO market. The company had been set to list under the ticker OURA during the…
- Market Flux Event
FDA Approves Eli Lilly Onswik as First Once-Weekly Basal Insulin for Type 2 Diabetes
The U.S. Food and Drug Administration approved Eli Lilly's Onswik, generic name insulin efsitora alfa-gobe, as a once-weekly basal insulin injection for adults living with type 2 diabetes…
- Unusual Volume
Novo Nordisk Stock Falls Up to 7.4% as 2030 Strategy and $23 Billion Pipeline Target Disappoint Investors
Novo Nordisk shares plunged as much as 7.4% on Monday after CEO Mike Doustdar used a Capital Markets Day in London to lay out a long-term growth strategy that failed to calm investor…
- Market Flux Event
FDA Accepts Cogent Biosciences NDA for Bezuclastinib as Novo Nordisk Rebrands Amid Lilly Competition
Cogent Biosciences secured a key regulatory milestone as the FDA accepted its New Drug Application for bezuclastinib in patients with Advanced Systemic Mastocytosis, assigning a PDUFA…
- Top Mover
Morgan Stanley Hosts Major Healthcare Conference, Expands Bitcoin Holdings Past $609 Million and Downgrades Stellantis
Morgan Stanley's 24th Annual Global Healthcare Conference dominated the firm's activity on September 14, drawing presentations from dozens of companies including Eli Lilly, Pfizer, Johnson…
- Market Flux Event
Dozens of Healthcare and Biotech Companies Showcase Pipelines and Launch Plans at Morgan Stanley, Jefferies and H.C. Wainwright Conferences
September 14, 2026 saw a broad wave of healthcare and biotech presentations across three major investor conferences, with the Morgan Stanley 24th Annual Global Healthcare Conference drawing…
- Unusual Volume
Novartis Shares Crash 14% to 52-Week Low After Three Drug Trial Failures in One Week
Novartis suffered a devastating session on Tuesday, September 8, with its U.S.-listed shares tumbling roughly 14% to close at $137.70, a fresh 52-week low, after two major late-stage…
- Market Flux Event
Trump Announces Drug Pricing Deals With Nine More Pharma Companies, Expanding Most Favored Nation Push
President Trump announced on August 31 that his administration has struck drug pricing agreements with nine additional pharmaceutical and biotech companies, committing them to sell…
- Market Flux Event
FDA Expands Mounjaro Label to Reduce Heart Attack and Stroke Risk in Type 2 Diabetes Patients
The FDA approved an expanded label for Eli Lilly's Mounjaro (tirzepatide) to reduce major adverse cardiovascular events, including heart attack and stroke, in high-risk patients with type 2…
- Top Mover
Eli Lilly Hits All-Time High as Stock Surges 4% and Deal With Amplitude Expands RNA Vaccine Pipeline
Eli Lilly shares climbed 4.0% on August 19, 2026, reaching a record intraday high of $1,249.95 as a broad biopharma rally, triggered by Moderna's cancer-vaccine breakthrough, lifted the…
- Most Active
OmniAb Signs Eli Lilly Ion Channel Deal Worth Up to $370M, Raises 2026 Cash Guidance
OmniAb struck a global collaboration and license agreement with Eli Lilly for a new ion channel drug discovery program, with OmniAb eligible to receive an upfront payment plus up to $370…
- Market Flux Event
Eli Lilly Wins European Approval for Weight Loss Pill Foundayo as BMY Scores FDA Nod for Myeloma Drug
Eli Lilly secured the first European regulatory approval for its oral weight loss pill Foundayo in the United Kingdom, intensifying a direct battle with Novo Nordisk, whose oral Wegovy was…
- Top Mover
Eli Lilly's Oral Weight-Loss Pill Foundayo Wins First European Approval in the UK
Britain's Medicines and Healthcare products Regulatory Agency approved Eli Lilly's oral GLP-1 pill orforglipron, branded Foundayo, on August 10, making the UK the first European country to…
- Market Flux Event
Eli Lilly Wins UK Approval for Oral Weight-Loss Pill Foundayo as Biotech Sector Sees Wave of Catalysts
Eli Lilly's oral weight-loss pill orforglipron, branded Foundayo, secured its first European regulatory approval in Britain on August 10, extending the drug's commercial footprint beyond…